Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

ARNA 2.70 +0.14 (5.47%)
price chart
Can Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Keep Up with Analyst Expectations?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported an earnings surprise of 26.67% when the company last reported earnings for the period ending on 2015-06-30.
Arena Pharmaceuticals, Inc. Analyst Rating Update  News Watch International
Company Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Drops by -8.75%  Insider Trading Report
Fear These Three Biotech Stocks: Arena Pharmaceuticals, Inc. (ARNA), Amicus ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ended at $2.56 by losing 5.54%. The $656.48M company on August 18, 2015 announced that it has partnered with GoodData, a leading provider of Insights-as-a-Service, to create a highly visual solution that ...
Arena Pharmaceuticals (ARNA) Is Today's Strong On High Volume Stock
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Price Target Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): According to 4 Analysts, The short term target price has been estimated at $ 5.63.
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Large Inflow of Net ...  American Trade Journal
Short Interest Update on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), According to the latest information the short interest in Arena Pharmaceuticals, Inc. plummeted by 2.2% or 617,472 shares. The final shorts are 11.6% of the total floated shares. The positions dropped from ...
Stock in Focus - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)  Vanguard Tribune
Healthcare Sector Movers: Arena Pharmaceuticals, Inc. (ARNA), Relypsa, Inc ...  WallStreet Scope
Arena Pharmaceuticals, Inc. Short Interest Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stated gains of 512,286 shares or 1.8% in the short interest. The short interest registered from 27,821,423 on July 31,2015 to 28,333,709 on August 14,2015.
Zacks Short Term Rating on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Research firm Zacks has rated Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and has ranked it at 3, indicating that for the short term the shares are a hold.
Arena Pharmaceuticals (ARNA) Rises: Stock Adds 5.7% in Session  Zacks.com
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Analyst Rating in Focus  Investor Newswire
Small cap stock picking: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Arrowhead ...
Small cap stock picking: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Arrowhead Research Corp (NASDAQ:ARWR), Omeros Corporation (NASDAQ:OMER).
Company Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Drops by -4.26%
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has lost 4.26% during the past week and dropped 25.11% in the last 4 weeks.
Arena Pharmaceuticals Inc (NASDAQ:ARNA) near 52-week low , short interest down
Arena Pharmaceuticals Inc (NASDAQ:ARNA) (TREND ANALYSIS) shares were traded with a significant increase in volume. The stock closed last trading session at $3.02, down by -6.21%, with a volume of 4,443,906 shares against an average volume for the ...
3 Biotech Stocks Are Getting Crushed: Pharmaceuticals, Inc. (NASDAQ:ARNA ...  Wall Street Point
Healthcare Top Decliners: Omeros Corporation (NASDAQ:OMER), Arena ...  Stock Transcript